In a carefully controlled clinical trial across 29 countries, researchers have achieved what seemed impossible just years ago: one in five chronic hepatitis B patients experienced what scientists call a "functional cure" using a new drug called bepirovirsen combined with standard treatment. This breakthrough, published on May 28 in the New England Journal of Medicine, represents a stunning leap forward in a disease that has confounded medicine for decades and quietly devastates more than 240 million people worldwide.
Hepatitis B is the most common liver virus on Earth and the leading cause of liver cancer, yet it earns the grim nickname "silent killer" because only 13 percent of those infected even know they have it. The virus can hide in the body for years, slowly destroying the liver without triggering obvious symptoms until serious damage has already occurred. For decades, scientists have chased a cure while patients resigned themselves to lifelong antiviral therapy and the persistent stigma of being a hepatitis B carrier. Current standard treatment alone achieves a functional cure—meaning the immune system keeps the virus under control without medication for more than six months—in just 3 percent of patients after eight to 10 years of therapy.
The phase III trial tested bepirovirsen in 1,838 adults with chronic hepatitis B across 29 countries, and the results fundamentally shift what's possible. Approximately one in five participants achieved that functional cure. The gap between 3 percent and 20 percent may seem like simple arithmetic, but for patients living with a serious chronic condition, it represents the difference between resignation and hope.
"We've not had a treatment come close to this level of cure," says Seng Gee Lim, the study's co-author and director of hepatology at the National University Health System in Singapore. "I think my patients will be extremely delighted to have this treatment available." Anna Suk-Fong Lok, the director of clinical hepatology and assistant dean for clinical research at the University of Michigan Medical School and a leading expert on chronic hepatitis B, echoed that optimism in published commentary on the trial: "After many failed trials in the last 10 years, the B-Well Trials' results provide hope that functional cure for hepatitis B is feasible."
The drug works by harnessing the body's own immune system to control the virus more effectively than standard treatment alone. The most dramatic results appeared in patients whose disease was already better controlled, though researchers note the results cannot yet be generalized to those with cirrhosis, coinfection with HIV, or severe disease—populations excluded from the trials.
Jane Davies, an infectious disease specialist at the Royal Darwin Hospital in Australia and director of Hepatitis Australia, called these "promising initial results" and an important step forward in tackling a disease that remains a global health burden. The hepatitis B virus is remarkably contagious, transmitted through blood and bodily fluids and capable of surviving on surfaces for up to a week, making prevention and treatment equally urgent priorities.
For hundreds of millions of people living with this chronic infection, the possibility of a functional cure—especially one that works five to six times better than current options—offers something that has long felt out of reach: genuine hope for a different future.